Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

514G3

Other · developed by XBiotech

Phase 1/2 Most advanced trial (none active)

XBIT Developer

1 Registered trials

What is 514G3?

514G3 is an investigational drug studied in Staphylococcus Aureus Bacteremia.

At a glance

Drug type: Other
Therapy area: Infectious disease
Developer: XBiotech, Inc. (XBIT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 3PV0P81X8Q

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02357966	Phase 1/2	Staphylococcus Aureus Bacteremia	Completed	XBIT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Staphylococcus Aureus Bacteremia

More from XBiotech

Hutrukin Phase 1 Natrunix Phase 2 Vilamakitug Phase 2

Sources

ClinicalTrials.gov NCT02357966

Updated Oct 3, 2026. Something wrong or missing? Report it on the XBIT page.

Follow XBIT, the company behind 514G3

See XBIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XBIT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z